POTTER v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

CourtDistrict Court, D. New Jersey
DecidedJune 14, 2023
Docket3:15-cv-07658
StatusUnknown

This text of POTTER v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (POTTER v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
POTTER v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC., (D.N.J. 2023).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

IN RE VALEANT PHARMACEUTICALS Civil Action No. 15-7658 (MAS) (LHG) tON. NAL, INC, SECURITIES MEMORANDUM OPINION

SHIPP, District Judge This matter comes before the Court upon Lead Plaintiff City of Tucson, together with and on behalf of the Tucson Supplemental Retirement System’s (“Lead Plaintiff’) Motion to Adopt the Special Master’s November 30, 2022, Report & Recommendation Denying PricewaterhouseCoopers LLP’s (“PwC”) Motion to Dismiss Count III of the Corrected Second Amended Consolidated Complaint (ECF No. 1077). (ECF No. 1080.) PwC opposed Lead Plaintiff's Motion to Adopt and objected to the Special Master’s Report and Recommendation. (ECF Nos. 1082, *1084.)' Lead Plaintiff opposed PwC’s objections and replied to its opposition (ECF No. *1163), and PwC replied to Lead Plaintiff's opposition (ECF No. *1170). The Court has carefully considered the parties’ submissions and decides the matter without oral argument pursuant to Local Civil Rule 78.1. For the reasons set forth herein, Lead Plaintiff's Motion to Adopt is granted. L BACKGROUND The Court previously summarized many of the factual allegations at issue in this matter, and the Court assumes the parties’ familiarity with those allegations. (See, e.g., ECF No. 216.) The facts relevant to resolve the instant Motion, which the parties do not dispute, are thoroughly

' ECF numbers preceded by an asterisk reflect the redacted version of the cited document.

outlined in the Special Master’s November 2022 Report and Recommendation (“November 2022 R&R”), and the Court adopts those facts here. (Nov. 2022 R&R 2-15, ECF No. 1077.) In pertinent part, in February 2022, Lead Plaintiff? filed a Second Amended Consolidated Complaint (““SACC”) which added Count III against PwC, asserting violations of Section 10(b) of the Securities Exchange Act of 1934 (“Section 10(by’) and Securities Exchange Commission Rule 10b-5 (“Rule 10b-5”) (“Count IIT”).? (See SACC 4] 55, 561-648, ECF No. 952.) PwC now moves to dismiss Count IT. (See generally PwC’s Moving Br., ECF No. *969.) Count If centers around PwC’s audit report for Valeant Pharmaceuticals International, Inc.’s (“Valeant”) 2014 financial statements (the “2014 Audit Report’). (See, SACC 569-70.) In the 2014 Audit Report, PwC opined that: (1) Valeant’s 2014 financial statements “present[ed| fairly, in all material respects” Valeant’s financial position and results of its operations as of and for the year ending December 31, 2014; and (2) Valeant maintained “‘in all material respects, effective internal control over financial reporting as of December 31, 2014.” (SACC ¥ 563; Nov. 2022 RER 6.) Lead Plaintiff alleges that PwC’s 2014 Audit Report assured investors that Valeant’s financial statements complied with generally accepted accounting principles (“GAAP”), that Valeant had effective internal controls, and that PwC conducted its audit in accordance with professional standards. (SACC 4] 563; Nov. 2022 R&R 25.) Lead Plaintiff contends, however, that

2 On September 15, 2022, Plaintiff City of Tucson, together with and on behalf of the Tucson Supplemental Retirement System, replaced TIAA as Lead Plaintiff. (See ECF No. 1029.) 3 The prior complaint asserted a violation of Section 11 of the Securities Act of 1933 against PwC but raised no fraud-based claims. (See ECF No. 80.)

these statements were false and misleading when made to investors because the true facts known by PwC, or that PwC recklessly disregarded, were that: (a) Valeant’s 2014 financial statements were inaccurate because they overstated revenue by $58 million, net income by $33 million, and earnings per share by $0.09 for the year ended December 31, 2014; (b) Valeant’s 2014 financial statements were not prepared in conformity with GAAP because the financial statements failed to disclose Philidor as a material acquisition/business combination and variable interest entity (“VIE”) in violation of GAAP; (c) Valeant’s internal controls were not effective because they suffered from the existence of two material weaknesses — an improper tone at the top of the organization and a failure to adequately design and maintain effective controls over the review, approval, and documentation of the accounting and disclosure for non-standard revenue transactions at quarter ends; (d) Philidor was an acquired business that had been excluded from Valeant’s internal control testing; and (e) PwC did not conduct its 2014 audit of Valeant’s financial statements and internal controls in accordance with the standards of the Public Company Accounting Oversight Board (“PCAOB”). (SACC 4 564; Nov. 2022 R&R 48.) Lead Plaintiffincludes numerous further allegations that Lead Plaintiff claims sufficiently demonstrate a strong inference of scienter on the part of PwC. (SACC §§ 562, 574-640.) These allegations include, in part: (1) that there were red flags regarding Valeant’s improper business practices and the backgrounds of Valeant management and directors (SACC Ff 574-81); (2) that there were red flags suggesting that Valeant was improperly engaged in earnings manipulations at quarter ends (id. [§ 582-95); (3) that PwC reviewed a $131 million credit increase granted to Philidor only ten days before the acquisition closed but still documented that there was “no instance in which credit increased unusually high through one single

transaction;” (id. § 562); and (4) that PwC knowingly or recklessly disregarded that Philidor sales transactions violated GAAP (id. □□ 596-613). PwC argues that Lead Plaintiff's allegations fall short of the demanding standard for pleading an outside auditor’s scienter. (Nov. 2022 R&R 15.) First, PwC looks to concessions in the SACC to demonstrate that Lead Plaintiff's allegations negate rather than support a finding of scienter, including that (1) Valeant provided false information to PwC in connection with the audit, (2) the amount of misstated revenue was relatively small (less than 1% of revenue), and (3) PwC conducted multiple audit procedures related to the Philidor sales. Vd. at 15-17.) PwC further contends that Lead Plaintiff does not allege sufficient facts to give rise to a strong inference of scienter because Lead Plaintiff fails to allege facts that show PwC had both motive and opportunity to commit fraud or facts that constitute strong circumstantial evidence of PwC’s conscious misbehavior or recklessness. (/d. at 18.) I. STANDARD OF REVIEW The Court reviews objections to the Special Master’s findings of fact and conclusions of law de novo. (Order 4, ECF No. 484); Fed. R. Civ. P. 53(f)(3)-(4). The Court “may adopt or affirm, modify, wholly or partly reject or otherwise reverse, or resubmit [the matter] to the master with instructions.” Fed. R. Civ. P. 53(f)(1); (Order 4.) LEGAL STANDARD When analyzing a Rule 12(b)(6) motion, district courts conduct a three-part analysis. First, the court must “tak[e] note of the elements a plaintiff must plead to state a claim.” Ashcroft v. Iqbal, 556 U.S. 662, 675 (2009). Second, the court must accept as true all of a plaintiff's well-pleaded factual allegations and construe the complaint in the light most favorable to the plaintiff. Fowler v. UPMC Shadyside, 578 F.3d 203, 210 (3d Cir. 2009). The court, however, must

disregard any conclusory allegations proffered in the complaint. /d. at 210-11.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Tellabs, Inc. v. Makor Issues & Rights, Ltd.
551 U.S. 308 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Matrixx Initiatives, Inc. v. Siracusano
131 S. Ct. 1309 (Supreme Court, 2011)
In Re: Rockefeller Center Properties, Inc. Securities Litigation, Charal Investment Company Inc., a New Jersey Corporation C.W. Sommer & Co., a Texas Partnership, on Behalf of Themselves and All Others Similarly Situated Alan Freed Jerry Crance Helen Scozzanich Sheldon P. Langendorf Rita Walfield Robert Flashman Renee B. Fisher Foundation Inc. Frank Debora Wilson White Stanley Lloyd Kaufman, Jr. Joseph Gross v. David Rockefeller Goldman Sachs Mortgage Co. Goldman Sachs Group Lp Goldman Sachs & Co. Whitehall Street Real Estate Limited Partnership v. Wh Advisors Inc. v. Wh Advisors Lp v. Daniel M. Neidich Peter D. Linneman Richard M. Scarlata Frank Debora Wilson White Stanley Lloyd Kaufman, Jr. Joseph Gross, Charal Investment Company Inc., a New Jersey Corporation C.W. Sommer & Co., a Texas Partnership, on Behalf of Themselves and All Others Similarly Situated Alan Freed Jerry Crance Helen Scozzanich Sheldon P. Langendorf Rita Walfield Robert Flashman Renee B. Fisher Foundation Inc. Frank Debora Wilson White Stanley Lloyd Kaufman, Jr. Joseph Gross v. David Rockefeller Goldman Sachs Mortgage Co. Goldman Sachs Group Lp Goldman Sachs & Co. Whitehall Street Real Estate Limited Partnership v. Wh Advisors Inc. v. Wh Advisors Lp v. Daniel M. Neidich Peter D. Linneman Richard M. Scarlata Charal Investment Company Inc. C.W. Sommer & Co. Renee B. Fisher Foundation Helen Scozzanich Jerry Crance Alan Freed Sheldon P. Langendorf Rita Walfield Robert Flashman
311 F.3d 198 (Third Circuit, 2002)
Institutional Investors Group v. Avaya, Inc.
564 F.3d 242 (Third Circuit, 2009)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
GSC Partners CDO Fund v. Washington
368 F.3d 228 (Third Circuit, 2004)
Klein v. Autek Corp.
147 F. App'x 270 (Third Circuit, 2005)
OFI Asset Management v. Cooper Tire & Rubber
834 F.3d 481 (Third Circuit, 2016)
Rothman v. Gregor
220 F.3d 81 (Second Circuit, 2000)
Fan v. StoneMor Partners LP
927 F.3d 710 (Third Circuit, 2019)
McLean v. Alexander
599 F.2d 1190 (Third Circuit, 1979)

Cite This Page — Counsel Stack

Bluebook (online)
POTTER v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/potter-v-valeant-pharmaceuticals-international-inc-njd-2023.